Signature published by C Laurent et al (Supplemental Table 1 In addition to be able to activate the classical pathway, CD40 is a strong inducer of the PD-L1 and PD-L2, being up-regulated in L.CD40 B-cell lymphoma ( Figure 1A ). IL-10 7 8 receptor signaling is mediated by the JAK1 and Tyk2 tyrosine kinase that leads to activation 7 9 of STAT3 transcription factor, STAT3 being a major inducer of PD-L1 gene expression (9). heterogeneous on CD8 T-cells ( Figure 4B ). lymphoma, a tumor which is constantly associated with both NF-κB and STAT3 activation. In activation but may exhibit a chronic active BCR (13) and are sensitive to BTK inhibitors (14).
STAT3 activation mainly found in ABC-DLBCLs and is associated with poor survival (15). involved NF-κB activation by CD40 but also BTK and JAK/STAT signaling, the latter example. Indeed, PD-L1 expression could be down-regulated after treated with NF-κB, cancers. Indeed, in vivo blockade of PD-L1 was able to rapidly repress expansion of these B- PD-1/PD-L1 axis and TKI specific for the JAK/STAT or the BCR/BTK pathway could be of Spleen from mice were collected and immune cells were filtered through a sterile nylon analyzed using Kaluza Flow Cytometry software 1.2 (Beckman Coulter; France). For in vivo proliferation, mice were injected intraperitoneally with 2 mg BrdU (Sigma-
Aldrich, US), 18 hours before isolating cells. Splenocytes were stained for B220 and phases using the FITC-BrdU Flow Kit (BD Pharmingen; US). English editing. contributed to the writing of the manuscript. J.F. and N.F. designed and directed the study,
contributed to the experiments, analyzed the results and wrote the manuscript. 
